Verrica Pharmaceuticals (NASDAQ:VRCA) Rating Lowered to “Strong Sell” at Wall Street Zen

Verrica Pharmaceuticals (NASDAQ:VRCA) was downgraded by Wall Street Zen from a “sell” rating to a “strong sell” rating in a research note issued on Saturday, Wall Street Zen reports.

Other equities analysts also recently issued reports about the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of Verrica Pharmaceuticals in a research note on Tuesday, October 13th. Lake Street Capital initiated coverage on Verrica Pharmaceuticals in a research note on Thursday, August 27th. They set a “buy” rating and a $9.00 price objective on the stock. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average price target of $12.67.

Verrica Pharmaceuticals Price Performance

VRCA opened at $3.19 on Friday. The company has a 50-day moving average of $4.24 and a 200-day moving average of $5.51. The company has a market capitalization of $54.80 million, a P/E ratio of -1.91 and a beta of 1.69. Verrica Pharmaceuticals has a 1-year low of $3.08 and a 1-year high of $9.82. The company has a debt-to-equity ratio of 0.18, a quick ratio of 1.33 and a current ratio of 1.45.

Institutional Trading of Verrica Pharmaceuticals

A hedge fund recently raised its position in Verrica Pharmaceuticals stock. Fifth Third Bancorp lifted its holdings in Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) by 100.0% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 28,000 shares of the company’s stock after buying an additional 14,000 shares during the quarter. Fifth Third Bancorp owned approximately 0.16% of Verrica Pharmaceuticals worth $134,000 as of its most recent filing with the SEC. 42.45% of the stock is currently owned by institutional investors and hedge funds.

About Verrica Pharmaceuticals

Verrica Pharmaceuticals Inc is a dermatology-focused biopharmaceutical company developing and commercializing therapies for skin diseases that have limited or inadequate treatment options. The company’s activities center on prescription products designed for use by dermatologists and other healthcare professionals.

Verrica’s lead commercial product is YCANTHE (cantharidin) topical solution, 0.7%, a prescription treatment approved by the U.S. Food and Drug Administration for molluscum contagiosum in adults and children two years of age and older.